Danish firm Bavarian Nordic has a portfolio of patents for vaccines and cancer treatments, but likes to keep some of its cards close to its chest, as LSIPR finds out.
One week after the September 11 attacks in 2001, letters containing anthrax spores started appearing in the US postal system. Infected envelopes were sent to media offices and two US senators. The attack killed five people in what the Federal Bureau of Investigation described as one of the worst biological attacks in American history.
The incident sparked fears of a similar attack, followed by calls for a strategy to manage potential outbreaks of infectious diseases, including smallpox.
Although smallpox was declared officially eradicated after a global vaccination programme led by the World Health Organization, the virus still exists in laboratory archives and repositories controlled by the UN.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Trade secrets, IP strategy, Bavarian Nordic, Vaccines, Smallpox